Smithfield Trust Co Has $890,000 Position in Bristol-Myers Squibb (NYSE:BMY)

Smithfield Trust Co lifted its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 17,223 shares of the biopharmaceutical company’s stock after buying an additional 218 shares during the period. Smithfield Trust Co’s holdings in Bristol-Myers Squibb were worth $890,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the stock. LRI Investments LLC bought a new position in shares of Bristol-Myers Squibb in the 1st quarter valued at about $143,000. Lazard Asset Management LLC grew its holdings in Bristol-Myers Squibb by 51.5% during the first quarter. Lazard Asset Management LLC now owns 1,731,255 shares of the biopharmaceutical company’s stock worth $93,884,000 after purchasing an additional 588,799 shares during the period. Steel Grove Capital Advisors LLC increased its position in Bristol-Myers Squibb by 442.7% during the first quarter. Steel Grove Capital Advisors LLC now owns 37,657 shares of the biopharmaceutical company’s stock worth $2,042,000 after buying an additional 30,718 shares during the last quarter. Kestra Advisory Services LLC increased its holdings in shares of Bristol-Myers Squibb by 15.8% during the 1st quarter. Kestra Advisory Services LLC now owns 221,492 shares of the biopharmaceutical company’s stock worth $12,011,000 after acquiring an additional 30,297 shares during the last quarter. Finally, BOKF NA raised its stake in Bristol-Myers Squibb by 23.0% in the 1st quarter. BOKF NA now owns 143,343 shares of the biopharmaceutical company’s stock valued at $7,596,000 after acquiring an additional 26,816 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of the company’s stock in a transaction that occurred on Friday, November 1st. The stock was acquired at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Stock Up 0.6 %

Shares of BMY opened at $58.22 on Friday. The firm has a 50 day simple moving average of $53.46 and a two-hundred day simple moving average of $47.61. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $61.08. The company has a market cap of $118.08 billion, a P/E ratio of -16.22, a P/E/G ratio of 15.62 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. Bristol-Myers Squibb’s revenue was up 8.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.00 EPS. Research analysts forecast that Bristol-Myers Squibb will post 0.93 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 4.12%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is -66.85%.

Analysts Set New Price Targets

BMY has been the topic of several research reports. Jefferies Financial Group upped their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a report on Wednesday, August 28th. Leerink Partners raised shares of Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their price target for the company from $55.00 to $73.00 in a report on Tuesday, November 12th. Leerink Partnrs upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 12th. UBS Group upped their target price on Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research report on Wednesday, October 9th. Finally, Barclays boosted their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, Bristol-Myers Squibb presently has an average rating of “Hold” and an average target price of $54.07.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.